Dr. reddy's laboratories announces the launch of lansoprazole dr orally disintegrating tablets in the u.s. market

Hyderabad, india & princeton, n.j.--(business wire)--dr. reddy's laboratories ltd. (bse: 500124, nse: drreddy, nyse: rdy, nseifsc: drreddy, along with its subsidiaries together referred to as “dr. reddy's”) today announced the launch of lansoprazole dr orally disintegrating tablets, a therapeutic equivalent generic version of prevacid solutab delayed-release orally disintegrating tablets, 15 mg and 30 mg, approved by the u.s. food and drug administration (usfda). the prevacid® brand and generic
RDY Ratings Summary
RDY Quant Ranking